1.History of the Korean Society of Psychopharmacology.
Korean Journal of Psychopharmacology 2000;11(2):97-99
No abstract available.
Psychopharmacology*
2.History of the Korean Society of Psychopharmacology.
Korean Journal of Psychopharmacology 2000;11(2):97-99
No abstract available.
Psychopharmacology*
3.Neuroscience-based Nomenclature (NbN) for Clinical Psychopharmacology and Neuroscience.
Hiroyuki UCHIDA ; Shigeto YAMAWAKI ; Won Myong BAHK ; Duk In JON
Clinical Psychopharmacology and Neuroscience 2016;14(2):115-116
No abstract available.
Neurosciences*
;
Psychopharmacology*
4.PsychoPharmacology of OCD and Rerlated Disorders in Children and Adolescents.
Korean Journal of Psychopharmacology 2000;11(4):313-326
No abstract available.
Adolescent*
;
Child*
;
Humans
;
Psychopharmacology*
5.New Publication of the English Language Journal "Clinical Psychopharmacology and Neuroscience" in the Korean College of Neuropsychopharmacology.
Journal of Korean Neuropsychiatric Association 2004;43(1):6-9
Recently, the Korean College of Neuropsychopharmacolgy (KCNP) published an English language journal "Clinical Psychopharmacology and Neuroscience" for the purpose of international communications in the area of neuropsychopharmacology and related biological psychiatry. Historically, it is the first foreign language journal published in the Korean psychiatric society. This is writing to the background of publishing an English language journal in the perspectives of the limitations of Korean language journal and the international communications with researchers all over the world. The major concerns in publishing an English language journal are discussed. The future plan of continuously publishing "Clinical Psychopharmacology and Neuroscience" and some suggestions for the researchers who are going to submit manuscripts and to read this journal are described. We hope this is helpful for the publication of English language journal planning in the editorial committee of the Korean Neuropsychiatric Association.
Biological Psychiatry
;
Hope
;
Psychopharmacology*
;
Publications*
;
Writing
6.A New Goal of Treatment for Schizophrenia: Quality of Life.
Kyoung Uk LEE ; Won Myong BAHK
Korean Journal of Psychopharmacology 2006;17(1):13-23
Improvement of psychopharmacology resulted in changes in therapeutic target for patients with schizophrenia. Although the control of psychotic symptoms are considered to be the primary goal of treatment in schizophrenia, in recent years, functional recovery and improvement of quality of life (QoL) has been highlighted as the new therapeutic target. In this article, we reviewed the definition, assessment tools, and recent studies which have been done in Korea. QoL is complex and heterogenous concept, thus there have been no gold-standard measures for QoL. Standardization of assessment tools for Koreans has set the infrastructure for QoL researches in patients with schizophrenia. More researches are needed in this area, and it could provide information for the development of psychosocial program and systemic support for improving schizophrenic patient's QoL.
Humans
;
Korea
;
Psychopharmacology
;
Quality of Life*
;
Schizophrenia*
7.The Consideration for Revision of the Korean Medication Algorithm for Schizophrenia.
Jung Seo YI ; Yong Min AHN ; Won Myong BAHK ; Jun Soo KWON
Korean Journal of Psychopharmacology 2004;15(3):276-283
After publishing 2001 version of the Korean Medication Algorithm for Schizophrenia, the strategy of pharmacologic treatment for schizophrenia has been altered with the rapid advancement in the area of psychopharmacology. Currently, the feasibility of this algorithm has been evaluated. Guidelines require updating when significant new evidence appears. Recently, several guidelines of the treatment of schizophrenia including the APA practice guideline, the Expert Consensus Guideline Series and the Texas Medication Algorithm Project (TMAP) Antipsychotic Algorithm for Schizophrenia were revised. In this review, the authors briefly discussed the problems and limitations of the Korean Medication Algorithm for Schizophrenia and presented the direction of future revision on the model of above-mentioned guidelines.
Consensus
;
Drug Therapy
;
Methods*
;
Practice Guidelines as Topic
;
Psychopharmacology
;
Schizophrenia*
;
Texas
8.Phenomenological Psychopathology.
Journal of Korean Neuropsychiatric Association 2011;50(2):97-115
Phenomenology was founded in the 19th century by Edmund Husserl. Apart from natural sciences and metaphysics, phenomenology is presented as a rigorous scientific discipline, which aims to provide an understanding of the subjective experiences of human beings. After the eras of descriptive and dynamic psychiatry, phenomenological methods were adopted by psychiatry, and phenomenological psychopathology suggested a new perspective for understanding the pathological experiences of psychiatric patients. However, after the development of psychopharmacology and the operational diagnostic system, the center of phenomenology in psychopathology was moved from comprehensive understanding to simple description. Thus, phenomenological psychopathology in its original meaning did not get remarkable repercussions, especially in the English-speaking world. In this article, some major concepts of phenomenology will be briefly presented and then phenomenological psychopathology in its original meaning will be introduced. Secondly, as an example of its application, symptoms of schizophrenia will be interpreted in terms of phenomenological psychopathology. Finally, the authors will present a neurobiological interpretation of the phenomenological psychopathology of schizophrenia and suggest a possible role of phenomenological psychopathology in mitigating the impasse in psychiatric genetics research.
Humans
;
Metaphysics
;
Natural Science Disciplines
;
Neurobiology
;
Psychopathology
;
Psychopharmacology
;
Schizophrenia
9.Antidepressants in the Treatment of Various Subtypes of Depressive Disorders.
Korean Journal of Psychopharmacology 2010;21(1):5-13
Depressive disorders have many faces in clinical features, long-term course, prognosis, and the patients with depressive disorders are not homogeneous group. So, there have been many subtypes of depression suggested and described by clinicians and researchers. But, there is few evidences which support unique pathophysiology and clinical implication about each subtype. The treatment of various subtype of depression is not also specified according to scientific evidence. Nowadays, the rapid development of psychopharmacology and many new antidepressants are making it more possible for clinician to choose antidepressant according to the subtypes of depression and to the characteristics of patients. Therefore, we reviewed the clinical evidence of the treatment for various subtypes of depressive disorders and tried to recommend more efficient antidepressant treatment, although there is a few data for subtypes of depressive disorders. We concluded that the specific choice of antidepressant for each subtypes of depression is not yet possible, because the current subtyping of depression is not clear in many aspects, and the clinical trials have focused mainly in depression in a whole. From now on, more efforts is needed about the more specified subtyping and more specified treatment in order to get more efficacy, safety, and the satisfaction of patients with depressive disorders.
Antidepressive Agents
;
Depression
;
Depressive Disorder
;
Humans
;
Prognosis
;
Psychopharmacology
10.Feasibility of Korean Medication Algorithm for Bipolar Disorder(I): Global Assessment.
Chan Hyung KIM ; Kyung Joon MIN ; Young Chul SHIN ; Bo Hyun YUN ; Hyun Sang CHO ; Duk In JON ; Young Kee KIM ; Jun Soo KWON ; Won Myong BAHK
Korean Journal of Psychopharmacology 2005;16(3):225-233
OBJECTIVE: The Korean College of Neuro psychopharmacology and the Korean Academy of Schizophrenia developed the Korean algorithm project for bipolar disorder to aid clinical decisions. The purpose of this study was to assess the feasibility of Korean Medication Algorithm for Bipolar Disorder (KMAP-BP) in clinical settings in Korea. METHODS: A total of 126 bipolar patients were enrolled at 17 centers. Among them, 92 patients were treated according to the algorithm. All subjects were assessed over a 4-month period. Prescribing investigators were able to change the recommended treatment strategies of the algorithm if necessary. RESULTS: Overall ratings were favorable, with investigators stating that the overall quality of this algorithm was "good" or "no need to revise". Of manic patients, the majority (79%) showed treatment response (YMRS improvement > or =50%) at the first stage. CONCLUSION: These results suggest that this algorithm can be useful in clinical practices. However, some problems should be solved in the next version of KMAP-BP.
Bipolar Disorder
;
Humans
;
Korea
;
Psychopharmacology
;
Research Personnel
;
Schizophrenia